---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-23-000063"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:01:38.602842+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65

## Summary
- Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.
- GAAP net income $26.1M ($0.49 diluted EPS) vs $17.3M ($0.33) YoY.
- Adjusted non-GAAP net income $34.8M ($0.65 diluted EPS) vs $20.7M ($0.39) YoY.
- Completed BAQSIMI acquisition June 30; glucagon, phytonadione, and newer products drove growth.
- Six-month: revenue $285.7M, GAAP net income $52.2M ($0.99 EPS), adj. net income $66.9M ($1.27 EPS).

## SEC filing metadata
- accession: 0001297184-23-000063
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000063/0001297184-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000063/amph-20230808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-23-000063
- JSON: https://secwatch.observer/filing/0001297184-23-000063.json
- Plain text: https://secwatch.observer/filing/0001297184-23-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.